Photo from Andrew Hahn/X
Dec 7, 2023, 18:39
Andrew Hahn: Our latest paper on the efficacy of contemporary TT after patients with sarcomatoid and/or rhabdoid dedifferentiation progress on ICT
Andrew Hahn, Genitourinary Medical Oncologist at MD Anderson Cancer Center, shared on X/Twitter:
“Our latest paper on the efficacy of contemporary TT after patients with sarcomatoid and/or rhabdoid dedifferentiation progress on ICT. In 57 patients, median time on TT was 6.4 m and ORR was 20%. (See here)
Rhabdoid dediff had longer time on TT than sarcomatoid dediff (15.6 vs 6.1 m, HR 0.44). Despite improvements with ICT, S/R RCC needs better treatment options after ICT.”
For more details click here.
Source: Andrew Hahn/X
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
Jan 23, 2025, 21:19
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 21:18
Jan 23, 2025, 20:48